Buy Ziprasidone HCl (Geodon) online

How and where to order Geodon (Ziprasidone Hydrochloride) 20 mg, 40 mg, 80 mg capsules or tablets online:

Shop:DRUGS FOR HEALTH - 10% discount coupon DFHDCC
Prices:from $0.66 per pill
Forms:Ziprasidone HCl 20 mg, 40 mg, 80 mg tablets and capsules
Quantity:10-360 pills
Type:Ziprasidone brand, Zipsydon brand, Geodon generic
Payment:Visa, Mastercard, AmEx, Cryptocurrency
Delivery:Regular and express mail service
Shipping:Worldwide, including USA, UK, Europe, Canada, Australia

Indications and usage:

Ziprasidone is an atypical antipsychotic. In choosing among treatments, prescribers should be aware of the capacity of Geodon to prolong the QT interval and may consider the use of other drugs first.

Geodon (Ziprasidone Hydrochloride) capsules and tablets are indicated for the:

  • treatment of schizophrenia in adults.
  • acute treatment of adults as monotherapy of manic or mixed episodes associated with bipolar I disorder.
  • maintenance treatment of bipolar I disorder as an adjunct to lithium or valproate in adults.
    Geodon (Ziprasidone Mesylate) for injection is indicated for the:

  • acute treatment of agitation in schizophrenic patients in adults.

    Dosage and administration:

    Administer capsules orally with food. Do not open, crush, or chew.

    Schizophrenia: initiate at 20 mg twice daily. Daily dosage may be adjusted up to 80 mg twice daily. Dose adjustments should occur at intervals of not less than 2 days. Safety and efficacy has been demonstrated in doses up to 100 mg twice daily. The lowest effective dose should be used.

    Acute treatment of manic/mixed episodes of bipolar I disorder: initiate at 40 mg twice daily. Increase to 60 mg or 80 mg twice daily on day 2 of treatment. Subsequent dose adjustments should be based on tolerability and efficacy within the range of 40-80 mg twice daily.

    Maintenance treatment of bipolar I disorder as an adjunct to lithium or valproate: continue treatment at the same dose on which the patient was initially stabilized, within the range of 40-80 mg twice daily.

    Acute treatment of agitation associated with schizophrenia (intramuscular administration): 10 mg-20 mg up to a maximum dose of 40 mg per day. Doses of 10 mg may be administered every 2 hours. Doses of 20 mg may be administered every 4 hours.


    In case of acute ziprasidone overdosage, establish and maintain an airway and ensure adequate oxygenation and ventilation. Intravenous access should be established, and gastric lavage (after intubation, if patient is unconscious) and administration of activated charcoal together with a laxative should be considered. The possibility of obtundation, seizure, or dystonic reaction of the head and neck following overdose may create a risk of aspiration with induced emesis.

    Cardiovascular monitoring should commence immediately and should include continuous electrocardiographic monitoring to detect possible arrhythmias. If antiarrhythmic therapy is administered, disopyramide, procainamide, and quinidine carry a theoretical hazard of additive QT-prolonging effects that might be additive to those of ziprasidone.

    Hypotension and circulatory collapse should be treated with appropriate measures such as intravenous fluids. If sympathomimetic agents are used for vascular support, epinephrine and dopamine should not be used, since beta stimulation combined with alpha-1 antagonism associated with ziprasidone may worsen hypotension. Similarly, it is reasonable to expect that the alpha-adrenergic-blocking properties of bretylium might be additive to those of ziprasidone, resulting in problematic hypotension.

    In cases of severe extrapyramidal symptoms, anticholinergic medication should be administered. There is no specific antidote to ziprasidone, and it is not dialyzable. The possibility of multiple drug involvement should be considered. Close medical supervision and monitoring should continue until the patient recovers.

    Dosage forms and strengths:

  • Geodon (Ziprasidone Hydrochloride) capsules 20 mg, 40 mg, 60 mg, 80 mg.
  • Geodon (Ziprasidone Mesylate) for injection 20 mg/ml single-dose vials.


  • Do not use Geodon in patients with a known history of QT prolongation.
  • Do not use ziprasidone in patients with recent acute myocardial infarction.
  • Do not use this medication in patients with uncompensated heart failure.
  • Do not use in combination with other drugs that have demonstrated QT prolongation.
  • Do not use in patients with known hypersensitivity to ziprasidone.

    Warnings and precautions:

  • Cerebrovascular adverse reactions in elderly patients with dementia-related psychosis: increased incidence of cerebrovascular adverse reactions (e.g., stroke, transient ischemic attack).
  • QT interval prolongation: Geodon (Ziprasidone) use should be avoided in patients with bradycardia, hypokalemia or hypomagnesemia, congenital prolongation of the QT interval, or in combination with other drugs that have demonstrated QT prolongation.
  • Neuroleptic malignant syndrome (NMS): potentially fatal symptom complex has been reported with antipsychotic drugs. Manage with immediate discontinuation of drug and close monitoring.
  • Severe cutaneous adverse reactions, such as drug reaction with eosinophilia and systemic symptoms (DRESS) and Stevens-Johnson syndrome has been reported with ziprasidone exposure. DRESS and other severe cutaneous adverse reactions (SCAR) are sometimes fatal. Discontinue this medicine if DRESS or SCAR are suspected.
  • Tardive dyskinesia: may develop acutely or chronically.
  • Metabolic changes: atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/ cerebrovascular risk. These metabolic changes include hyperglycemia, dyslipidemia, and weight gain.
  • Hyperglycemia and diabetes mellitus (DM): monitor all patients for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Patients with DM risk factors should undergo blood glucose testing before and during treatment.
  • Dyslipidemia: undesirable alterations have been observed in patients treated with atypical antipsychotics.
  • Weight gain: weight gain has been reported. Monitor weight gain.
  • Rash: discontinue in patients who develop a rash without an identified cause.
  • Orthostatic hypotension: use with caution in patients with known cardiovascular or cerebrovascular disease.
  • Leukopenia, neutropenia, and agranulocytosis has been reported with antipsychotics. Patients with a pre-existing low white blood cell count (WBC) or a history of leukopenia/neutropenia should have their complete blood count (CBC) monitored frequently during the first few months of therapy and should discontinue Geodon at the first sign of a decline in WBC in the absence of other causative factors.
  • Seizures: use cautiously in patients with a history of seizures or with conditions that lower seizure threshold.
  • Potential for cognitive and motor impairment: patients should use caution when operating machinery.
  • Suicide: closely supervise high-risk patients.

    Adverse reactions, side effects:

    Commonly observed adverse reactions (incidence >= 5% and at least twice the incidence for placebo) were:

  • Schizophrenia: somnolence, respiratory tract infection.
  • Manic and mixed episodes associated with bipolar disorder: somnolence, extrapyramidal symptoms, dizziness, akathisia, abnormal vision, asthenia, vomiting.
  • Intramuscular administration ( >= 5% and at least twice the lowest intramuscular ziprasidone group): headache, nausea, somnolence.

    To report suspected side effects of Geodon (Ziprasidone) pills and injections contact Pfizer pharmaceutical company or your local FDA.

    Drug interactions:

  • Ziprasidone should not be used in combination with other drugs that have demonstrated QT prolongation.
  • The absorption of ziprasidone is increased up to two-fold in the presence of food.
  • The full prescribing information contains additional drug interactions.

    Related medications:

  • Disulfiram tablets
  • Modafinil for ADHD

    Use in specific populations:


    May cause extrapyramidal and/or withdrawal symptoms in neonates with third trimester exposure.


    Limited data from a published case report indicate the presence of ziprasidone in human milk.

    Pediatric use

    The safety and effectiveness of this drug have not been established in pediatric patients.

    Ziprasidone was studied in one 4-week, placebo-controlled trial in patients 10 to 17 years of age with bipolar I disorder. However, the data were insufficient to fully assess the safety of Geodon in pediatric patients. Therefore, a safe and effective dose for use could not be established.

    Geriatric use

    Of the total number of subjects in clinical studies of ziprasidone, 2.4% were 65 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. Nevertheless, the presence of multiple factors that might increase the pharmacodynamic response to ziprasidone, or cause poorer tolerance or orthostasis, should lead to consideration of a lower starting dose, slower titration, and careful monitoring during the initial dosing period for some elderly patients.

    Geodon (Ziprasidone Mesylate) intramuscular has not been systematically evaluated in elderly patients (65 years and over).

    Renal impairment

    Intramuscular ziprasidone should be administered with caution to patients with impaired renal function as the cyclodextrin excipient is cleared by renal filtration.

    Age and gender effects

    In a multiple-dose (8 days of treatment) study involving 32 subjects, there was no difference in the pharmacokinetics of ziprasidone between men and women or between elderly (>65 years) and young (18 to 45 years) subjects. Additionally, population pharmacokinetic evaluation of patients in controlled trials has revealed no evidence of clinically significant age or gender-related differences in the pharmacokinetics of ziprasidone. Dosage modifications for age or gender are, therefore, not recommended.


    Based on in vitro studies utilizing human liver enzymes, ziprasidone is not a substrate for CYP1A2; smoking should therefore not have an effect on the pharmacokinetics of ziprasidone. Consistent with these in vitro results, population pharmacokinetic evaluation has not revealed any significant pharmacokinetic differences between smokers and nonsmokers.

    Drug abuse and dependence:

    Ziprasidone (Geodon) has not been systematically studied, in animals or humans, for its potential for abuse, tolerance, or physical dependence. While the clinical trials did not reveal any tendency for drug-seeking behavior, these observations were not systematic and it is not possible to predict on the basis of this limited experience the extent to which ziprasidone will be misused, diverted, and/or abused once marketed. Consequently, patients should be evaluated carefully for a history of drug abuse, and such patients should be observed closely for signs of ziprasidone misuse or abuse (e.g., development of tolerance, increases in dose, drug-seeking behavior).

    Patient counseling information:

    Administration information for capsules

    Advise patients to take Geodon (Ziprasidone Hydrochloride) capsules and tablets whole. Do not open, crush, or chew the capsules. Instruct patients to take Geodon capsules with food for optimal absorption. The absorption of ziprasidone is increased up to two-fold in the presence of food.

    QTc prolongation

    Advise patients to inform their health care providers of the following: history of QT prolongation; recent acute myocardial infarction; uncompensated heart failure; prescription of other drugs that have demonstrated QT prolongation; risk for significant electrolyte abnormalities; and history of cardiac arrhythmia.

    Instruct patients to report the onset of any conditions that put them at risk for significant electrolyte disturbances, hypokalemia in particular, including but not limited to the initiation of diuretic therapy or prolonged diarrhea. In addition, instruct patients to report symptoms such as dizziness, palpitations, or syncope to the prescriber.

    Severe cutaneous adverse reactions

    Instruct patients to report to their health care provider at the earliest onset any signs or symptoms that may be associated with Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) or with severe cutaneous adverse reactions, such as Stevens-Johnson syndrome.


    Advise pregnant women to notify their healthcare provider if they become pregnant or intend to become pregnant during treatment with Geodon. Advise patients that this medication may cause extrapyramidal and/or withdrawal symptoms (agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, and feeding disorder) in a neonate. Advise patients that there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to ziprasidone during pregnancy.


    Advise breastfeeding women using this drug to monitor infants for excess sedation, irritability, poor feeding, and extrapyramidal symptoms (tremors, and abnormal muscle movements) and to seek medical care if they notice these signs.


    Advise females of reproductive potential that Geodon may impair fertility due to an increase in serum prolactin levels. The effects on fertility are reversible.

    Where to buy ziprasidone online:

    To purchase Geodon (Ziprasidone Hydrochloride) capsules or tablets from reliable online pharmacies and drugstores at low prices please use resources described above on this webpage.

    Here is a list of popular medications containing ziprasidone as a main active pharmaceutical ingredient; their trade names, forms, doses, companies - manufacturers, distributors, suppliers, researchers and developers:

    Trade name of the drug Pharmaceutical forms and doses Companies
  • Capsules; Oral; Ziprasidone Hydrochloride 20 mg, 40 mg, 60 mg, 80 mg
  • Injectable; Injection; Ziprasidone Hydrochloride 20 mg / ml
  • Suspension; Oral; Ziprasidone Mesylate 50 mg / 5 ml
  • Pfizer
  • Roerig
  • Viatris
  • Zeldox
  • Capsules; Oral; Ziprasidone Hydrochloride Monohydrate 20 mg, 40 mg, 60 mg, 80 mg
  • Injectable; Injection; Ziprasidone Mesylate 20 mg / ml
  • Pfizer
  • Ben Venue Laboratories
  • Heinrich Mack Nachfolger
  • Viatris
  • Zipsydon
  • Tablets; Oral; Ziprasidone 20 mg, 40 mg, 60 mg, 80 mg
  • Sun Pharmaceutical Industries
  • Zipwell
  • Capsules; Oral; Ziprasidone Hydrochloride 20 mg, 40 mg, 60 mg, 80 mg
  • Actavis